Legato Capital Management LLC Takes $1.60 Million Position in Tandem Diabetes Care, Inc. $TNDM

Posted by Stanley Muller on May 24th, 2026

Legato Capital Management LLC acquired a new stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Free Report) during the fourth quarter, Holdings Channel.com reports. The firm acquired 72,580 shares of the medical device company’s stock, valued at approximately $1,595,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Caitong International Asset Management Co. Ltd raised its holdings in shares of Tandem Diabetes Care by 200.0% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,205 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 1,470 shares in the last quarter. Quarry LP raised its holdings in shares of Tandem Diabetes Care by 2,597.1% in the 3rd quarter. Quarry LP now owns 3,695 shares of the medical device company’s stock valued at $45,000 after purchasing an additional 3,558 shares in the last quarter. Aster Capital Management DIFC Ltd raised its holdings in shares of Tandem Diabetes Care by 485.1% in the 3rd quarter. Aster Capital Management DIFC Ltd now owns 5,149 shares of the medical device company’s stock valued at $63,000 after purchasing an additional 4,269 shares in the last quarter. Creative Financial Designs Inc. ADV raised its holdings in shares of Tandem Diabetes Care by 36.0% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 3,431 shares of the medical device company’s stock valued at $75,000 after purchasing an additional 909 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its holdings in shares of Tandem Diabetes Care by 36.6% in the 4th quarter. Farther Finance Advisors LLC now owns 3,600 shares of the medical device company’s stock valued at $79,000 after purchasing an additional 965 shares in the last quarter.

Analyst Upgrades and Downgrades

TNDM has been the topic of several research analyst reports. The Goldman Sachs Group cut their price target on shares of Tandem Diabetes Care from $28.00 to $25.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. UBS Group reiterated a “neutral” rating and set a $22.00 price target (up from $17.00) on shares of Tandem Diabetes Care in a research note on Friday, February 20th. Piper Sandler upgraded shares of Tandem Diabetes Care from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $21.00 to $33.00 in a research note on Tuesday, March 17th. Weiss Ratings lowered shares of Tandem Diabetes Care from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, May 11th. Finally, Rothschild & Co Redburn set a $45.00 price target on shares of Tandem Diabetes Care in a research note on Friday, April 24th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $29.63.

Read Our Latest Research Report on TNDM

Tandem Diabetes Care Stock Down 5.0%

Shares of NASDAQ:TNDM opened at $14.97 on Friday. The company has a market cap of $1.03 billion, a price-to-earnings ratio of -10.69 and a beta of 1.64. The firm’s 50-day simple moving average is $19.34 and its 200-day simple moving average is $20.26. The company has a quick ratio of 3.07, a current ratio of 3.58 and a debt-to-equity ratio of 4.54. Tandem Diabetes Care, Inc. has a fifty-two week low of $9.98 and a fifty-two week high of $29.65.

Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) last issued its earnings results on Thursday, May 7th. The medical device company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.16. The business had revenue of $247.22 million for the quarter, compared to the consensus estimate of $240.41 million. Tandem Diabetes Care had a negative net margin of 9.20% and a negative return on equity of 53.88%. The business’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.66) earnings per share. As a group, equities research analysts predict that Tandem Diabetes Care, Inc. will post -0.79 earnings per share for the current year.

Tandem Diabetes Care Profile

(Free Report)

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.